EMEA: Public statement on fee reductions for designated orphan medicinal products

EMEA:
Public statement on fee reductions for designated orphan medicinal products . This includes fees for pre-authorisation activities such as protocol assistance (scientific advice), and for products using the centralised procedure: the application for marketing authorisation, inspections and post-authorisation activities such as variations, annual fees, etc. (04 January 2009)